Supernus Pharmaceuticals Inc (SUPN)

Receivables turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	US$ in thousands	607,521	673,056	560,079	500,962	392,755
Receivables	US$ in thousands	—	165,497	148,932	140,877	87,332
Receivables turnover		—	4.07	3.76	3.56	4.50

December 31, 2023 calculation

Receivables turnover = Revenue ÷ Receivables
= $607,521K ÷ $—K
= —

The receivables turnover of Supernus Pharmaceuticals Inc has shown a generally increasing trend over the past five years, indicating the company's ability to efficiently collect on its credit sales. The ratio has increased from 3.69 in 2020 to 4.21 in 2023. This signifies that, on average, the company collected its accounts receivable approximately 4.21 times a year in 2023.

A higher receivables turnover ratio is usually preferred as it suggests that the company is collecting its outstanding receivables more efficiently. Supernus Pharmaceuticals Inc's increasing receivables turnover ratio could indicate improved credit policies, effective collections strategies, or a customer base that is prompt in paying their debts.

Overall, the upward trend in receivables turnover for Supernus Pharmaceuticals Inc demonstrates strong management of accounts receivable and suggests potential improvements in working capital management and cash flow efficiency.